CytoMed Therapeutics (FRA:F98) 3-Year EBITDA Growth Rate : -35.50% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics 3-Year EBITDA Growth Rate?

CytoMed Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.11.

During the past 3 years, the average EBITDA Per Share Growth Rate was -35.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of CytoMed Therapeutics was -35.50% per year. The lowest was -35.50% per year. And the median was -35.50% per year.

Competitive Comparison of CytoMed Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, CytoMed Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's 3-Year EBITDA Growth Rate falls into.

CytoMed Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CytoMed Therapeutics (FRA:F98) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CytoMed Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (FRA:F98) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (FRA:F98) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

GDTC:USA

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

CytoMed Therapeutics (FRA:F98) Headlines

No Headlines